Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these compounds boost insulin release and suppress gluca

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in the